New combo therapy aims to save nerves in advanced ear cancer

NCT ID NCT07370337

Recruiting now Disease control Sponsor: Eye & ENT Hospital of Fudan University Source: ClinicalTrials.gov ↗

First seen Jan 29, 2026 · Last updated May 02, 2026 · Updated 14 times

Summary

This study is testing a combination of chemotherapy and an immunotherapy drug (tislelizumab) given before surgery for people with advanced squamous cell carcinoma of the ear canal. The goal is to shrink the tumor enough to allow surgeons to remove it while preserving important nerves and blood vessels. About 50 adults with previously untreated, locally advanced cancer will participate to see if this approach improves outcomes and reduces damage to nearby structures.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF EXTERNAL AUDITORY CANAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Li Wang
RECRUITING

Shanghai, Shanghai Municipality, 200031, China

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED TUMOR SQUAMOUS CELL CARCINOMA OF EXTERNAL AUDITORY CANAL